OpenScience.ink

3 weeks ago • Frontiers in endocrinology

Big metabolic improvement with tirzepatide in a patient with partial fat loss after stem cell transplantCase Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation.

🎖️ Top 10% Journal

3 weeks ago • The Journal of international medical research

Glucagon-like peptide-1 receptor agonists and their effects on body weight and kidney protein levels in people with and without type 2 diabetesEffect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.

📖 Top 50% Journal

3 weeks ago • Childhood obesity (Print)

How Caregivers’ Use of GLP-1 Medicines May Affect Family Food Habits and Children's Health BehaviorsBeyond the Individual: Family-Level Impacts of Caregiver GLP-1 Use on Food Environments and Child Health Behaviors.

📖 Top 30% Journal

3 weeks ago • Nature metabolism

Stopping GLP-1RA treatment linked to higher risk of depression and anxiety in people with type 2 diabetesAssociation of GLP-1RA discontinuation and risk of depressive and anxiety disorders in people with type 2 diabetes: a cohort study.

🥇 Top 1% Journal

3 weeks ago • Journal of obesity & metabolic syndrome

Obesity in Adults with Type 1 DiabetesObesity in Adults with Type 1 Diabetes Mellitus.

🥉 Top 5% Journal

3 weeks ago • Surgical endoscopy

Stopping a diabetes drug for two weeks around surgery and its link to leftover stomach contents during upper digestive tract examsEffect of two-week perioperative glucagon-like peptide-1 receptor agonist interruption on retained gastric contents during esophagogastroduodenoscopy: a retrospective, observational study.

📖 Top 20% Journal

3 weeks ago • Advances in therapy

Using GLP-1 Receptor Agonists to Treat Obesity and Type 2 Diabetes in Older Adults: Important Factors to ConsiderSpecial Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.

📖 Top 20% Journal

3 weeks ago • Journal of diabetes and metabolic disorders

Effects and safety of GLP-1 drugs on heart and metabolism health in overweight or obese Chinese adultsEfficacy and safety of GLP-1RA on cardio-metabolic outcomes in overweight or obese Chinese adults: a systematic review and meta-analysis.

📖 Top 50% Journal

3 weeks ago • Obstetrics and gynecology

Links Between Diabetes Drugs and Menstrual Changes in Women of Reproductive AgeAssociation of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.

🥉 Top 5% Journal

3 weeks ago • Journal of obesity & metabolic syndrome

Drug Treatments for Fatty Liver Disease Linked to Metabolism in the Age of Obesity and Metabolic MedicinePharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.

🥉 Top 5% Journal

3 weeks ago • Stem cell reports

GLP-1 influences bone marrow stem cell development through HIF-2-AKT signals and helps maintain spongy bone in steroid-related osteoporosisGLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis.

🥉 Top 5% Journal

3 weeks ago • Bioorganic chemistry

Designing small molecules that activate the GLP-1 receptor using lead compoundsLead-guided prodrug development of small molecules as GLP-1R agonists.

📖 Top 30% Journal

3 weeks ago • Advances in therapy

Combined Use of Two Diabetes Drugs in People with Type 2 Diabetes and Heart DiseaseBeyond Single-Class Therapy: Real-World Combined Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

📖 Top 20% Journal

3 weeks ago • Military medicine

Use Patterns of GLP-1 Medicines for Weight Management in Active Duty Service Members from 2021 to 2025Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.

📖 Top 50% Journal

3 weeks ago • Journal of Ayurveda and integrative medicine

The anti-diabetic effects of the herbal mix Varanadi Kashayam may involve boosting GLP-1 hormone and blocking DPP4 enzymeThe systemic anti-diabetic effect of polyherbal formulation Varanadi Kashayam is mediated through GLP-1 secretion and DPP4 inhibition.

📖 Top 50% Journal

3 weeks ago • Journal of virology

Glucagon-like peptide-1 receptor agonist may prevent lung scarring after COVID-19 in people with type 2 diabetesGlucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes.

4 weeks ago • NEJM catalyst innovations in care delivery

Expanding a Primary Care Weight Management Program Across the State to Improve Obesity CareBreaking Barriers in Obesity Care - Scaling a Primary Care Weight Management Program Statewide.

📖 Top 20% Journal

4 weeks ago • ACR open rheumatology

Autoimmune Disease Risk Linked to Different Diabetes Treatments: GLP-1RA, DPP-4i, and SGLT2iAutoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes.

📖 Top 20% Journal

4 weeks ago • Frontiers in immunology

How GLP-1 receptor activators may protect the brain and help treat neurological diseases by affecting metabolismGLP-1 receptor agonists in neurological diseases: mechanisms and therapeutic prospects from metabolism to neuroprotection.

🥉 Top 5% Journal

4 weeks ago • Journal of diabetes

Comparing Real-World and Clinical Trial Results for Incretin-Based Diabetes TreatmentsReal-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.

📖 Top 20% Journal

4 weeks ago • The lancet. Diabetes & endocrinology

Nutrition, body function, and mental health factors in incretin-based treatments for adults: Expert consensusNutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement.

🥇 Top 1% Journal

4 weeks ago • Scientific reports

Pregnancy outcomes linked to mothers' use of GLP-1 receptor agonist medications: a combined review and analysisPregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis.

📖 Top 20% Journal

4 weeks ago • Digestive diseases and sciences

Stomach Side Effects and Healthcare Use in Patients Taking Glucagon-Like Peptide-1 Medicines: A Real-World StudyIncidence of Gastrointestinal Adverse Events and Healthcare Resource Utilization in Patients Using Glucagon-Like Peptide-1 Analogs: A Real-World Study.

📖 Top 20% Journal

4 weeks ago • Frontiers in clinical diabetes and healthcare

Time-limited eating in adults with type 2 diabetes taking GLP-1 diabetes medications: case reportTime-restricted eating in adults with type 2 diabetes mellitus on concomitant glucagon-like peptide-1 receptor agonists: case report.

📖 Top 30% Journal

4 weeks ago • Obesity (Silver Spring, Md.)

How Drugs That Activate the Glucagon-Like Peptide-1 Receptor Affect Body Fat and MuscleGlucagon-Like Peptide-1 Receptor Agonist-Based Agents and Body Composition: Filling More Gaps.

🎖️ Top 10% Journal

4 weeks ago • Translational psychiatry

Comparing weight loss drugs that target blood sugar control in people with mental illnessGlucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.

🥉 Top 5% Journal

4 weeks ago • JACC. Heart failure

Tirzepatide's effects on obesity-related heart failure with preserved pumping function differ by sexEffects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.

🥇 Top 1% Journal

4 weeks ago • Neuroscience and biobehavioral reviews

Links Between Hormones, Appetite, and Mental Health in Older Women and What This Means for GLP-1 TreatmentThe neuroendocrine-appetite-mental health triangle in PMOS: Implications for GLP-1 receptor agonist therapy.

🥉 Top 5% Journal

4 weeks ago • Cell chemical biology

Interaction between GLP-1 and GIP receptors influences insulin-releasing signalsGLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways.

🥉 Top 5% Journal

4 weeks ago • Diabetes, obesity & metabolism

Brain and Mental Health Effects of Tirzepatide, Semaglutide, and Similar GLP-1 TreatmentsNeuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.

← prevpage 13 of 15next →

Latest GLP-1 Therapies Research Papers